20(S)-ginsenoside Rh2 inhibits angiotensin-2 mediated cardiac remodeling and inflammation associated with suppression of the JNK/AP-1 pathway - 04/12/23
, Guang Liang a, b, ⁎ Abstract |
Background |
Enhanced levels of angiotensin-2 (Ang-II) causes hypertensive heart failure (HHF) through non-hemodynamical and hemodynamical alterations. 20(S)-ginsenoside Rh2 (20(S)-Rh2) is a natural ginseng compound with numerous cardiovascular benefits. This investigation elucidates the influence of 20(S)-Rh2 on Ang-II-induced heart failure and cardiac alterations.
Methods |
Ang-II was administered in C57BL/6 mice for 4 weeks to induce HHF. In the last 2 weeks of treatment, 20(S)-Rh2 was orally administered in mice to assess the potential 20(S)-Rh2 mechanism. Subsequently, RNA sequencing was carried out.
Results |
It was indicated that 20(S)-Rh2 suppresses myocardial fibrosis, hypertrophy, and inflammation, thereby inhibiting cardiac disruption in Ang-II-challenged mice without affecting blood pressure. According to the RNA sequencing data, this cardio-protective effect was linked with the (JNK)/AP 1 pathway. 20(S)-Rh2 alleviated heart tissue and cardiomyocytes inflammation by inhibiting the Ang-II-mediated JNK/AP-1 pathway. Within cardiomyocytes, JNK or AP-1 absence abolished the anti-inflammatory effects of 20(S)-Rh2.
Conclusion |
This study investigation indicated that 20(S)-Rh2 prevents cardiovascular dysfunction induced by Ang-II induced by decreasing JNK-regulated inflammatory responses, providing evidence for its use as an efficient regimen for HHF.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Keywords : 20(S)-ginsenoside Rh2, Angiotensin II, C-Jun N-terminal kinase, Inflammation, Hypertensive heart failure
Plan
Vol 169
Article 115880- décembre 2023 Retour au numéro
Article précédent
- Irisin protected hemopoietic stem cells and improved outcome of severe bone marrow failure
- Hui Li, Dexiao Kong, Yi Zhao, Xia Liu, Fang Xiao, Xiaoyan Li, Jianting Hu, Yingjie Chen, Shengli Li, Baozhu Wang, Yuan Chen, Yang Jiang, Xiaoli Liu, Xiumei Feng, Yanan Guo, Xiaoli Feng, Jing Ren, Fang Wang, Ying Han, William Donelan, Lijun Yang, Dawei Xu, Dongqi Tang, Chengyun Zheng
- Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults
- Jia Yao Phuah, Brian M. Maas, Aimin Tang, Ying Zhang, Luzelena Caro, Radha A. Railkar, Michael D. Swanson, Yu Cao, Hankun Li, Brad Roadcap, Andrew P. Catchpole, Antonios O. Aliprantis, Kalpit A. Vora
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?